Author:
Umezu Tomohiro,Tsuneyama Koichi,Kanekura Kohsuke,Hayakawa Michiyo,Tanahashi Toshihito,Kawano Mitsuoki,Taguchi Y-h,Toyoda Hidenori,Tamori Akihiro,Kuroda Masahiko,Murakami Yoshiki
Abstract
AbstractStreptozotocin administration to mice (STZ-mice) induces type I diabetes and hepatocellular carcinoma (HCC). We attempted to elucidate the carcinogenic mechanism and the miRNA expression status in the liver and blood during the precancerous state. Serum and liver tissues were collected from STZ-mice and non-treated mice (CTL-mice) at 6, 10, and 12 W. The exosome enriched fraction extracted from serum was used. Hepatic histological examination and hepatic and exosomal miRNA expression analysis were serially performed using next-generation sequencing (NGS). Human miRNA expression analysis of chronic hepatitis liver tissue and exosomes, which were collected before starting the antiviral treatment, were also performed. No inflammation or fibrosis was found in the liver of CTL-mice during the observation period. In STZ-mice, regeneration and inflammation of hepatocytes was found at 6 W and nodules of atypical hepatocytes were found at 10 and 12 W. In the liver tissue, during 6–12 W, the expression levels of let-7f-5p, miR-143-3p, 148a-3p, 191-5p, 192-5p, 21a-5p, 22-3p, 26a-5p, and 92a-3p was significantly increased in STZ-mice, and anti-oncogenes of their target gene candidates were down-regulated. miR-122-5p was also significantly down-regulated in STZ-mice. Fifteen exosomal miRNAs were upregulated in STZ-mice. Six miRNAs (let-7f-5p, miR-10b-5p, 143-3p, 191-5p, 21a-5p, and 26a-5p) were upregulated, similarly to human HCC cases. From the precancerous state, aberrant expression of hepatic miRNAs has already occurred, and then, it can promote carcinogenesis. In exosomes, the expression pattern of common miRNAs between mice and humans before carcinogenesis was observed and can be expected to be developed as a cancer predictive marker.
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264 e1261-1273 e1261 (2012).
2. White, D. L., Thrift, A. P., Kanwal, F., Davila, J. & El-Serag, H. B. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 152, 812 e815-820 e815 (2017).
3. Global Burden of Disease Liver Cancer Group C., Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A. et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 3, 1683–1691 (2017).
4. Frey, S., Buchmann, A., Bursch, W., Schulte-Hermann, R. & Schwarz, M. Suppression of apoptosis in C3H mouse liver tumors by activated Ha-ras oncogene. Carcinogenesis 21, 161–166 (2000).
5. Park, T. J. et al. TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop. Hepatology 47, 1533–1543 (2008).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献